What’s Ahead for Zoetis Inc After Today’s Bearish Options Activity?

 What's Ahead for Zoetis Inc After Today's Bearish Options Activity?

In today’s session Zoetis Inc (ZTS) recorded an unusually high (808) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious ZTS decrease. With 808 contracts traded and 2654 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: ZTS170120P00048000 closed last at: $1.25 or 19% up. The stock increased 1.11% or $0.55 on November 23, hitting $50.18. About 2.06 million shares traded hands. Zoetis Inc (NYSE:ZTS) has risen 3.17% since April 22, 2016 and is uptrending. It has underperformed by 2.24% the S&P500.

Analysts await Zoetis Inc (NYSE:ZTS) to report earnings on February, 21. They expect $0.46 earnings per share, up 6.98% or $0.03 from last year’s $0.43 per share. ZTS’s profit will be $225.51M for 27.27 P/E if the $0.46 EPS becomes a reality. After $0.52 actual earnings per share reported by Zoetis Inc for the previous quarter, Wall Street now forecasts -11.54% negative EPS growth.

Zoetis Inc (NYSE:ZTS) Ratings Coverage

Out of 11 analysts covering Zoetis Inc (NYSE:ZTS), 8 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 73% are positive. Zoetis Inc has been the topic of 20 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Thursday, August 4 by Citigroup. As per Thursday, August 4, the company rating was maintained by Barclays Capital. The rating was maintained by Jefferies on Tuesday, March 15 with “Buy”. The rating was downgraded by Zacks on Monday, September 7 to “Hold”. William Blair upgraded the shares of ZTS in a report on Thursday, August 6 to “Outperform” rating. On Friday, May 6 the stock rating was downgraded by Goldman Sachs to “Sell”. The stock has “Buy” rating given by Stifel Nicolaus on Wednesday, June 1. The stock of Zoetis Inc (NYSE:ZTS) has “Outperform” rating given on Friday, September 11 by BMO Capital Markets. As per Tuesday, June 14, the company rating was maintained by Jefferies. Bank of America initiated Zoetis Inc (NYSE:ZTS) on Thursday, September 29 with “Buy” rating.

According to Zacks Investment Research, “Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.”

Insitutional Activity: The institutional sentiment increased to 1.19 in Q2 2016. Its up 0.11, from 1.08 in 2016Q1. The ratio is positive, as 48 funds sold all Zoetis Inc shares owned while 212 reduced positions. 72 funds bought stakes while 210 increased positions. They now own 451.82 million shares or 1.32% less from 457.84 million shares in 2016Q1.
Wilbanks Smith & Thomas Asset Mngmt Ltd Llc holds 6,433 shares or 0.03% of its portfolio. Park Circle owns 36,500 shares or 1.25% of their US portfolio. Trexquant Investment Limited Partnership accumulated 23,200 shares or 0.14% of the stock. Moreover, Insur Tx has 0.24% invested in Zoetis Inc (NYSE:ZTS) for 85,795 shares. Appleton Prtnrs Ma accumulated 104,235 shares or 1.01% of the stock. Bnp Paribas Inv Prtn Sa accumulated 93,997 shares or 0.04% of the stock. Melvin Cap Management L P holds 800,000 shares or 1.22% of its portfolio. The New York-based First Eagle Invest Mgmt Lc has invested 0.25% in Zoetis Inc (NYSE:ZTS). Signaturefd Ltd Limited Liability Company holds 1,134 shares or 0.01% of its portfolio. Shinko Asset Limited last reported 1,209 shares in the company. Ubs Asset Americas last reported 1.41M shares in the company. Pioneer Inv Incorporated has 3.08M shares for 0.53% of their US portfolio. 13D Management Ltd Llc last reported 264,220 shares in the company. Mufg Americas owns 3,397 shares or 0.01% of their US portfolio. Barrett Asset Mngmt Ltd Liability Co last reported 0.02% of its portfolio in the stock.

Insider Transactions: Since September 1, 2016, the stock had 1 insider purchase, and 4 selling transactions for $3.24 million net activity. $1.64 million worth of Zoetis Inc (NYSE:ZTS) was sold by Chen Heidi C. on Thursday, September 1. Shares for $102,680 were bought by MCCALLISTER MICHAEL B on Tuesday, September 6. $500,059 worth of shares were sold by PECK KRISTIN C on Tuesday, November 22. Lagano Roxanne sold $494,063 worth of stock. The insider Fenton Andrew sold 13,870 shares worth $710,838.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company has a market cap of $24.60 billion. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish , and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. It has a 36.32 P/E ratio. It operates through two divisions: the United States and International.

ZTS Company Profile

Zoetis Inc., incorporated on July 25, 2012, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Firm operates through two divisions: the United States and International. Within each of these divisions, the Company offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment